Busca avançada
Ano de início
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Activation of soluble guanylyl cyclase with inhibition of multidrug resistance protein inhibitor-4 (MRP4) as a new antiplatelet therapy

Texto completo
Mendes-Silverio, Camila B. [1] ; Lescano, Caroline H. [1] ; Zaminelli, Tiago [1] ; Sollon, Carolina [1] ; Anhe, Gabriel F. [1] ; Antunes, Edson [1] ; Monica, Fabiola Z. [1]
Número total de Autores: 7
Afiliação do(s) autor(es):
[1] Univ Campinas UNICAMP, Fac Med Sci, Dept Pharmacol, Sao Paulo - Brazil
Número total de Afiliações: 1
Tipo de documento: Artigo Científico
Fonte: Biochemical Pharmacology; v. 152, p. 165-173, JUN 2018.
Citações Web of Science: 3

The intracellular levels of cyclic GMP are controlled by its rate of formation through nitric oxide-mediated stimulation of soluble guanylate cyclase (sGC) and its degradation by phosphodiesterases. Multidrug resistance protein 4 (MRP4) expressed in human platelets pumps cyclic nucleotides out of cells. In search for new anti platelet strategies, we tested the hypothesis that sGC activation concomitant with MRP4 inhibition confers higher antiplatelet efficacy compared with monotherapy alone. This study was undertaken to investigate the pharmacological association of the sGC activator BAY 60-2770 with the MRP4 inhibitor MK571 on human washed platelets. Collagen- and thrombin-induced platelet aggregation and ATP-release reaction assays were performed. BAY 60-2770 (0.001-10 mu M) produced significant inhibitions of agonist-induced platelet aggregation accompanied by reduced ATP-release. Pre-incubation with 10 mu M MK571 alone had no significant effect on platelet aggregation and ATP release, but it produced a left displacement by about of 10-100-fold in the concentration-response curves to BAY 60-2770. Pre-incubation with MK571increased and decreased, respectively, the intracellular and extracellular levels of cGMP to BAY 60-2770, whereas the cAMP levels remained unchanged. The increased VASP-serine 239 phosphorylation in BAY 60-2770-treated platelets was enhanced by MK571. In Fluo-4-loaded platelets, BAY 60-2770 reduced the intracellular Ca2 + levels, an effect significantly potentiated by MK571. Flow cytometry assays showed that BAY 60-2770 reduces the alpha IIb beta 3 integrin activation, which was further reduced by MK571 association. Blocking the MRP4-mediated efflux of cGMP may be a potential mechanism to enhance the antiplatelet efficacy of sGC activators. (AU)

Processo FAPESP: 14/02130-1 - Papel da resistência à insulina no recrutamento pulmonar de eosinófilos em camundongos obesos: potencial anti-inflamatório e antioxidante do resveratrol
Beneficiário:Edson Antunes
Modalidade de apoio: Auxílio à Pesquisa - Regular